



Childhood Tuberculosis: Diagnosis, Treatment and Prevention of TB in HIV-infected Children

Celia DC Christie-Samuels Professor of Paediatrics (Infectious Diseases, Epidemiology and Public Health) University of the West Indies, Jamaica







The Problem

- One million new TB cases in children < 15 years old annually (WHO)
 - 11% of annual burden of cases
- Frequency depends on local TB/HIV epidemic, age structure, diagnostic tools, Rxn, contact investigation
- Children present with TB at any age
- Transmission to a child, results from close infected adult or adolescent contact
- TB infection \rightarrow Gohn focus \rightarrow regional adenopathy
- CMI halts disease progression, not functioning in HIV+



Children Living with HIV in Latin America and the Caribbean

Number of children living with HIV, 1990-2009

Caribbean

Central America



Number of children living with HIV



Fuente: UNAIDS. AIDS epidemic update 2010.

DIAGNOSIS

Clinical Presentations in Children

- Pulmonary TB
 - Mostly primary (not reactivation)
 - Uncomplicated
 - Unilateral adenopathy, cervical adenitis
 - Typical primary complex
 - Hilar, mediastinal adenopathy, lung opacity
 - Complicated
 - Lobar/ segmental adenopathy, bronchial compression
 - → atelectasis
 - Unilateral hyperinflation
 - Cavitation (rare)
 - TB bronchopneumonia
- Adenopathy, cervical adenitis
- Meningitis, tuberculomas
- Disseminated TB
- TB effusions
 - Pericarditis, pleuritis, peritonitis
- Spinal TB





Presentations of TB in Children with HIV

- Depends on stage of HIV
- Early HIV infection
 - TB presentation same as in HIV negative child
- Late HIV infection
 - Disseminated TB common, eg., meningitis, miliary, TB adenopathy
- Older children with TB/HIV
 - Same presentation as in HIV+ adults
- TB/HIV co-infection have longer hospital stays, malnutrition, higher mortality
- High index of suspicion for TB in HIV+ child
- Isolate *M. tuberculosis* from expectorated sputum, lymph node, CSF, effusions, tissue



Diagnosis of TB in HIV-infected Children



- Children do not produce sputum,
 - sputum, gastric washings usually M. tb-negative
- Careful history
 - Chronic cough > 2-3 weeks
 - Fever > 14 days, excluded common causes
 - Weight loss, failure to thrive
- Contact
 - Older household, caregiver with smear-positive TB
 - Especially HIV-infected adults

Clinical Examination

- Uncommon, highly suggestive
 - Gibbus, vertebral TB
 - Painless, cervical adenopathy with fistula formation



- Meningitis, not responding to antibiotics
- Pleuritis
- Pericarditis
- Ascites
- Painless adenopathy without fistula
- Painless joint enlargement
- Tuberculin hypersensitivity



Mantoux Tuberculin Skin Test



- Mantoux is positive with TB infection
- Mantoux+ with suggestive clinical symptoms is diagnostic of tuberculosis disease
 - Usually, 5 tuberculin units of PPD, trained health care workers administer test
 - High risk cases: TST > 5 mm
 - HIV+, close contacts to active TB, malnutrition, CXR suggestive of TB
 - All other children: TST > 10 mm induration,
 - Without regard to BCG vaccination status
 - Negative Mantoux does not exclude active TB disease, especially in HIV-infected children

Bacteriologic Confirmation

- Bacteriologic diagnosis preferable, using available specimens, especially for
 - Suspected drug resistance
 - HIV infection
 - Complicated/ severe cases
 - Uncertain diagnosis
- Sputum in children > 10 years
- Gastric aspirates
- MTB-RIF Xpert rapid dx also applies to children



Investigations for Pulmonary and Extra Pulmonary TB

- CXR changes of TB
 - Persistent lung opacities
 - Collapse consolidation
 - Hilar/mediastinal adenopathy
 - Opacification does not improve after antibiotics
 - Pleural effusions
- Histology, other special investigations (EPTB), CSF for TB meningitis
- PCR, interferon gamma release assay (IGRA), need more research for TB diagnosis in children
- CT, MRI's, bronchoscopy not usually recommended in children



HIV and TB Co-infections in Jamaican Children

- Significant increase in TB and TB/HIV coinfections at UHWI over four years
- 24 TB cases; All had BCG vaccine
- HIV–infected statistically more likely to be
 - Older
 - Have failure to thrive
 - Digital clubbing
 - Hepatomegaly
 - Splenomegaly
 - Generalized adenopathy
 - Negative Mantoux skin tests
- Appropriate in house-anti-TB Rxn, > 2 mos
- Death more likely and hospital stay longer in HIV infected vs., non-infected
- Household family members with active TB in 12 cases

Geoghagen M, Farr JA, Hambleton I, Pierre R, Christie CDC. *WIMJ*, 2004:53;5:339-345.





TREATMENT



Treating Childhood TB/HIV

• New smear negative PTB and less severe EPTB

- 2 mos INH, RIF PZA plus 4 mos INH, RIF

- New smear positive TB, new smear negative TB with extensive parenchymal involvement, Severe EPTB, or Severe concomitant HIV disease
 - 2 mos INH, RIF, PZA, ETH plus 4 mos INH, RIF
- Miliary TB and TB meningitis: use higher doses
 - 2 mos INH, RIF, PZA, STR plus 4 mos INH, RIF (WHO), or
 - 2 mos INH, RIF, PZA, STR (or ETH) plus 5-7 mos INH, RIF (AAP)
- Previously treated smear positive TB, with relapse, treatment after interruption, treatment failure

– 2 mos INH, RIF, PZA, ETH, STR plus 5 mos INH, RIF, ETH

- MDR TB
 - Special regimens, after consultation



Management of HIV-related TB

- Cotrimoxazole prophylaxis
 - Daily, prolongs survival and reduces respiratory infections and hospitalizations
 - All HIV+ children with advanced immune-suppression should be placed on cotrimoxazole
- Antiretroviral therapy
 - In HIV+ child, priority is to commence anti-TB drugs
 - Many drug-drug interactions between ARV's and RIF
 - Similar adverse reactions in anti-TB drugs and ARV's
 - When to start, not optimally determined for children
 - Consider degree of immune-suppression and child's progress during anti-TB Rxn

Timing of ART after anti-TB Treatment with Rifampin-containing regimen

- Extra Pulmonary TB
 - Start ART 2-8 wks after anti-TB treatment
- Pulmonary TB and lymph node TB
 - If clinical Mnx:
 - Start ART 2-8 wks after anti-TB Rxn or
 - Delay ART until anti-TB Rxn completed
 - CD4 values available
 - Severe/advanced immune deficiency
 - Start ART 2-8 wks after anti-TB Rnx
 - Mild or no immune deficiency
 - Delay ART until anti-TB Rxn is completed
- ART's:
 - < 3 years -- Triple NRTI 1st line regimen d4T /AZT + 3TC+ ABC, or 2 NRTI's + NVP
 - > 3 years: triple NRTI 1st line d4T/ AZT + 3TC +ABC, or standard 1st line 2 NRTI's + EFV



Special Considerations

- Immune reconstitution
 - Exacerbation of symptoms, signs, CXR manifestations after anti-TB therapy
 - Self limited, consider steroids
- Steroids for TB meningitis, miliary TB, airway obstruction by TB lymph glands, pericarditis
 - Improves survival, reduces mortality
 - Taper the dose after 4 weeks

Adherence

- Educate children and caregivers about TB and importance of completing therapy
- Support for care giver/family, record doses on Rxn card
- Treatment should be free, give fixed dose drugs
- Hospitalise children with severe TB for intensive management
 - Meningitis
 - Local vasculitis, tuberculoma, raised ICP and hydrocephalous
 - Miliary TB
 - Respiratory distress
 - Spinal TB
 - Severe adverse events, eg., hepatotoxicity
 - Adherence questionable

Monitoring During Treatment

- Symptom assessment
- Adherence
- Adverse events, eg., LFT's, haematology, rashes, IRIS
- Weight and medication adjustment for wt. gain
- Adherence and reviewing treatment card
- Followup sputum for AFB smear microscopy (if +)
 - Followup CXR's not routine, slow recovery
 - Non-response → drug-resistance, complications, nonadherence, other?

Isoniazid-resistant Disseminated *M. tuberculosis* in a Jamaican Infant with HIV/AIDS





I Singh-Minott, RB Pierre, O Olugbuyi, J Dunkley-Thompson, D Haughton, CDC Christie. West Indian Med J 2008;57(3):298-302.

PREVENTION

Child Contact

- Newly infected children with TB at high risk for miliary TB, meningitis if no preventive Rxn
- Close contact screening and management, adults family member, day-care contact with infectious TB
- Mantoux skin test-positive children:
 - If well (no symptoms, Normal CXR and growth), give INH preventive therapy x 6 months
 - If unwell, evaluate and treat for TB, if present
- Mantoux skin test negative children:
 - If well, IPT x 2 months, repeat Mantoux skin test
 - If positive at 2 months, continue IPT for 6-9 months
 - If negative at 2 months, discontinue IPT

Tuberculosis, Scabies and Chicken Pox Outbreaks in an Orphanage for Children with HIV/AIDS in Jamaica

- Concurrent outbreaks of tuberculosis (N=4), chicken pox (N=15), scabies (N=14) among 24 children residing in an AIDS orphanage
- Emphasizes need for:
 - Immunizations
 - Screening of staff and clients
 - Infection control
 - Education





Geoghagen M, Pierre R, Evans-Gilbert T, Rodriguez B, Christie CDC. *WIMJ*, 2004:53;5:346-351.

Intensive Case Finding and Prevention in Children with HIV – TB Screening

- Children living with HIV who do not have poor weight gain, fever, or current cough -- are unlikely to have active TB
- Children living with HIV who have poor weight gain, fever, or current cough, or contact history with a TB case – may have TB and should be evaluated for TB and other conditions. If the evaluation shows no TB, they should be offered IPT regardless of age.
 - Strong Recommendation, low quality of evidence

INH Regimen and Duration

- Children living with HIV who are more than 12 months of age and who are unlikely to have active TB on symptom screening and have no contact with a TB case should have 6 months of IPT (10 mg/kg/day)
- In children living with HIV who are less than 12 months of age, only those who have contact with a TB case and who are evaluated for TB should receive 6 months of IPT, if the evaluation shows no TB disease

- Strong recommendation, moderate evidence

- All children living with HIV who have successfully completed treatment for TB disease should receive INH for an additional 6 months
 - Conditional recommendation, moderate evidence

BCG lymphadenitis and Immune Reconstitution Syndrome in HIV-infected Children on Antiretroviral Therapy in Jamaica

- Three children with HIV infection developed BCG adenitis after initiation of highly active antiretroviral therapy (HAART)
- All "rapid progressors" with severe HIV/AIDS
- "Immune reconstitution syndrome"
- BCG vaccination should continue, per WHO policy



Dunkley-Thompson J, Pierre R, Steel-Duncan J, Palmer P, Davis D, Figueroa P, Christie CDC. West Indian Med J 2008;57(3):302-307.

BCG Vaccination in Children

- HIV-infected children who received BCG vaccine at risk for disseminated BCG disease
- Vaccinate:
 - HIV-uninfected children in high prevalence HIV+ populations
 - Infants born to women with unknown HIV status
 - HIV-exposed infants, asymptomatic, unknown HIV status
- Do not vaccinate:
 - Known HIV+ children, asymptomatic
 - Unknown HIV status in symptomatic children
 - Known HIV infected children, symptomatic



Thank you